Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) subsidiaries received clinical trial approval from China's National Medical Products Administration for two weight management tablets, HRS-1597 and SHR-1179, according to separate Tuesday filings with the Shanghai bourse.
Research and development investment for the HRS-1597 product so far reached 16.9 million yuan, while that for SHR-1179 is at 24.2 million yuan
The drug company's Hong Kong and Shanghai shares slipped 1% during Tuesday's morning session.